Clinical Trial: A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07801495) titled 'A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis' on Aug. 31.

Brief Summary: The purpose of this Phase 2a/b study is:

1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with psoriatic arthritis (PsA).

2. to determine the dose-response relationship of DDY391 in participants with PsA to support dose selection for Phase 3.

Study Start Date: Oct. 14

Study Type: INTERVENTIONAL

Condition: Moderate to Severe Psoriatic Arthritis

Intervention: DRUG: DDY391

DDY391

DRUG: Placebo

Matching placebo

Recruitment Status: NOT_YET_RECRU...